Patents Assigned to Concert Pharmaceuticals Inc.
-
Patent number: 10335413Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.Type: GrantFiled: March 15, 2018Date of Patent: July 2, 2019Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
-
Patent number: 10160778Abstract: This invention relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Y1a, Y1b, Y2a, Y2b, Y3a, and Y3b are each independently selected from hydrogen and deuterium, Y4a, Y4b, Y5a, Y5b, Y6a, Y6b, Y7a, Y7b, Y8a, Y8b, Y9a, Y9b, Y10a, Y10b, Y11a, Y11b, Y12a, Y12b, Y13a, Y13b, Y14a, Y14b, Y15a, Y15b, Y16a, Y16b, Y17a, Y17b, Y18a, and Y18b are each deuterium, X1a, X1b, X2a, X2b, X3, X4a, X4b, X5, and X6 are each independently selected from hydrogen and deuterium; and R is CD3. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a viral DNA polymerase inhibitor.Type: GrantFiled: October 27, 2015Date of Patent: December 25, 2018Assignee: Concert Pharmaceuticals, Inc.Inventor: Julie F. Liu
-
Publication number: 20180344727Abstract: Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.Type: ApplicationFiled: December 26, 2017Publication date: December 6, 2018Applicant: Concert Pharmaceuticals, Inc.Inventor: Amanda Thomas
-
Publication number: 20180327809Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?i receptor agonist that also has NMDA antagonist activity.Type: ApplicationFiled: December 12, 2017Publication date: November 15, 2018Applicant: Concert Pharmaceuticals, Inc.Inventor: Roger Tung
-
Publication number: 20180303848Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.Type: ApplicationFiled: July 2, 2018Publication date: October 25, 2018Applicant: Concert Pharmaceuticals, Inc.Inventor: Scott L. Harbeson
-
Patent number: 10039769Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.Type: GrantFiled: May 31, 2017Date of Patent: August 7, 2018Assignee: Concert Pharmaceuticals, Inc.Inventor: Scott L. Harbeson
-
Patent number: 10040748Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.Type: GrantFiled: April 11, 2016Date of Patent: August 7, 2018Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Adam J. Morgan
-
Patent number: 10022370Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: GrantFiled: April 14, 2017Date of Patent: July 17, 2018Assignee: Concert Pharmaceuticals, Inc.Inventors: Philip B. Graham, I. Robert Silverman
-
Patent number: 10017445Abstract: The present invention in one embodiment provides a compound of Formula I:(I), or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.Type: GrantFiled: July 12, 2013Date of Patent: July 10, 2018Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger D. Tung
-
Patent number: 9944635Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.Type: GrantFiled: December 3, 2015Date of Patent: April 17, 2018Assignee: Concert Pharmaceuticals, Inc.Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
-
Patent number: 9931343Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.Type: GrantFiled: December 14, 2016Date of Patent: April 3, 2018Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger D. Tung
-
Publication number: 20180086743Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.Type: ApplicationFiled: September 11, 2017Publication date: March 29, 2018Applicant: Concert Pharmaceuticals, Inc.Inventor: Scott L. Harbeson
-
Patent number: 9918987Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.Type: GrantFiled: October 12, 2016Date of Patent: March 20, 2018Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
-
Patent number: 9868976Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: GrantFiled: March 11, 2016Date of Patent: January 16, 2018Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger D. Tung
-
Patent number: 9840463Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).Type: GrantFiled: January 29, 2016Date of Patent: December 12, 2017Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger D. Tung
-
Patent number: 9815763Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.Type: GrantFiled: June 8, 2015Date of Patent: November 14, 2017Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger D. Tung
-
Patent number: 9783528Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.Type: GrantFiled: September 14, 2015Date of Patent: October 10, 2017Assignee: Concert Pharmaceuticals, Inc.Inventor: Scott L. Harbeson
-
Publication number: 20170281616Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: ApplicationFiled: April 14, 2017Publication date: October 5, 2017Applicant: Concert Pharmaceuticals, Inc.Inventors: Philip B. Graham, I. Robert Silverman
-
Patent number: 9776973Abstract: The present invention in one embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.Type: GrantFiled: November 30, 2016Date of Patent: October 3, 2017Assignee: Concert Pharmaceuticals, Inc.Inventor: Robert Silverman
-
Patent number: 9777009Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.Type: GrantFiled: July 27, 2016Date of Patent: October 3, 2017Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Adam J. Morgan